Are we ready for marginal hepatitis B core antibody-positive living liver donors?

Liver Transplantation

Volumn 9, Issue 8, 2003, Pages 833-836

  Fontana, Robert J ^a   Merion, Robert M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; LAMIVUDINE;

ANTIBODY DETECTION; CADAVER DONOR; CLINICAL PROTOCOL; EDITORIAL; GRAFT SURVIVAL; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION RISK; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; UNITED STATES;

EID: 0042062497     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50141     Document Type: Article

References (34)

1. Brown RS, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE, et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003;348:818-825.
2. Trotter JF, Wachs M, Everson GT, Kam I. Adult to adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002;346:1074-1082.
3. University Renal Research and Education Association. United Network for Organ Sharing Annual 2002 Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992-2001. Available at: http://www.ustransplant.org/annual.html. Accessed April 10, 2003.
4. Bak T, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, et al. Adult-to adult living donor liver transplantation using right-lobe grafts: Results and lessons learned from a single-center experience. Liver Transpl 2001;7:680-686.
5. Marcos A. Right-lobe living donor liver transplantation. Liver Transpl 2000;6(suppl 2):S64-S65.
6. Marcos A, Fisher RA, Ham J, Shiffman ML, Sanyal AJ, Luketic VA, et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000;69:1375-1379.
7. Beavers KL, Sandler RS, Shrestha R. Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: A systematic review. Liver Transpl 2002;8:110-117.
8. Cronin DC, Millis JM, Siegler M. Transplantation of liver grafts from living donors into adults - Too much, too soon. N Engl J Med 2001;344:1633-1637.
9. Surman OS. The ethics of partial-liver donation. N Engl J Med 2002;346:1038.
10. Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med 2000;343:404-410.
11. Karatzas T, Olson L, Ciancio G, Burke GW, Spire G, Cravero L, et al. Expanded liver donor age over 60 years for hepatic transplantation. Transplant Proc 1997;29:2830-2831.
12. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl 2002;8: 415-423.
13. Adam R, Bismuth H, Diamond T, Ducot B, Morino M, Astarcioglu J, et al. Effect of extended cold ischaemia with UW solution on graft function after liver transplantation. Lancet 1992;340:1373-1376.
14. D'Alessandro AM, Hoffman RM, Knechtle ST, Ororico JS, Becker YT, Musat A, et al. Liver transplantation from controlled non-heart-beating donors. Surgery 2000;128:579-588.
15. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002:8(suppl):S82-S87.
16. Feng S, Buell JF, Cherikh WS, Deng MC, Hanto DW, Kauffman HM, et al. Organ donors with positive viral serology or malignancy: Risk of disease transmission by transplantation. Transplantation 2002;74:1657-1663.
17. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997;113:1668-1674.
18. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001;7:513-517.
19. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058-1061.
20. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 2002:50:95-99.
21. Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Ng IO, Wong J. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl 2003;9:827-832.
22. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related transplants. Transplantation 1998;65:494-499.
23. Rokuhara A, Tanaka E, Yagi S, Mizokami M, Hashikura Y, Kawasaki S, Kiyosawa K. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation. J Med Virol 2000;62:471-478.
24. Fan ST, Lo CM, Liu CL, Yong BH, Chan JK, Ng IO. Safety of donors in liver donor liver transplantation using right lobe grafts. Arch Surg 2000;135:336-340.
25. Sakomoto S, Uemoto S, Uryuhara K, Kim ID, Kiuchi T, Egawa H, et al. Graft size assessment and analysis of donors for living donor liver transplantation using right lobe. Transplantation 2001;71:1407-1413.
26. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-298.
27. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right-lobe liver transplantation. Liver Transpl 2002;8:1114-1122.
28. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely occult? Hepatology 2001:34:194-203.
29. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-997.
30. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000;31:488-495.
31. Lo CM, Fung JT, Lau GK, Liu CL, Cheung ST, Lai CL, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003: 37:36-43.
32. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
33. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7:51-58.
34. Shiffman ML, Brown RS, Olthoff KM, Everson G, Miller C, Siegler M, Hoofnagle JH. Living donor liver transplantation: Summary of a Conference at The National Institutes of Health. Liver Transpl 2002;8:174-188.